期刊
BLOOD
卷 116, 期 14, 页码 2554-2558出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-11-253203
关键词
-
类别
资金
- National Institutes of Health [T-32-5CA009338, P01 CA95426, P01 CA103985, P50-CA140158]
- CLL Research Consortium [P01 CA81534-02]
- National Cancer Institute
- Leukemia & Lymphoma Society
- D. Warren Brown Foundation
Chronic lymphocytic leukemia (CLL) is an incurable progressive disease for which new therapies are required. Therapy with monoclonal antibodies (mAbs) has improved the outcome of patients with CLL, making further investigation of novel antibodies directed against alternative and specific targets on B cells an important area of translational research. We now describe functional properties of an antagonistic humanized mAb to CD74, milatuzumab, showing that milatuzumab combined with a crosslinking antibody induces cytotoxicity in vitro in CLL cells in a caspase-and stromal-independent manner associated with aggregation of CD74 on the cell surface. Furthermore, incorporation of milatuzumab into an immunoliposome induces even more of a cytotoxic response than in vitro crosslinking, representing a novel therapeutic formulation for this mAb. Based on these data, future development of the milatuzumab-immunoliposome formulation as a therapeutic agent for CLL is warranted. (Blood. 2010;116(14):2554-2558)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据